Log In
Print this Print this

galeterone (TOK-001)

  Manage Alerts
Collapse Summary General Information
Company Tokai Pharmaceuticals Inc.
DescriptionSelective androgen receptor modulator (SARM) and cytochrome P450 17 alpha-hydroxylase/C17,20 lyase (CYP17) inhibitor
Molecular Target Androgen receptor ; Cytochrome P450 17 alpha-hydroxylase/C17, 20 lyase (CYP17) (CYP17A)
Mechanism of ActionCytochrome P450 17alpha-hydroxylase/C17,20 lyase (CYP17) inhibitor; Androgen receptor inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationProstate cancer
Indication DetailsTreat AR-V7 positive metastatic castration-resistant prostate cancer (CRPC); Treat castration-resistant prostate cancer (CRPC)
Regulatory Designation

U.S. - Fast Track (Treat castration-resistant prostate cancer (CRPC))


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today